MSLN and neoplasm: Furthermore, it demonstrated selectivetargeting across MSLN-expressing xenografts (A431-G9, A431-H9, HCT116,and AsPC-1), consistently yielding a strong tumor signal even in HCT116tumors with low-to-moderate MSLN expression by IHC and WB.